Literature DB >> 6120951

Somatostatin sensitivity and growth hormone responses to releasing hormones and bromocryptine in acromegaly.

G F Pieters, J E Romeijn, A G Smals, P W Kloppenborg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 6120951     DOI： 10.1210/jcem-54-5-942

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  5 in total

1.  The growth hormone responses to L-dopa and TRH in acromegaly.

Authors:  I Jialal; C Naidoo; B C Nathoo; M C Rajput; S M Joubert
Journal:  J Endocrinol Invest       Date:  1984-06       Impact factor: 4.256

2.  The effects of growth hormone-releasing factor (GRF) and dopamine on growth hormone (GH) secretion in acromegaly.

Authors:  M Giusti; A Lomeo; G Mazzocchi; D Mignone; P Sessarego; M Monachesi; G Giordano
Journal:  J Endocrinol Invest       Date:  1985-06       Impact factor: 4.256

Review 3.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

Review 4.  Recent developments in acromegaly: a review.

Authors:  A Jadresic
Journal:  J R Soc Med       Date:  1983-11       Impact factor: 18.000

5.  The effect of long acting somatostatin analogue SMS 201-995 in acromegaly.

Authors:  C J Choi; D B Shin; S W Kim; I M Yang; J W Kim; Y S Kim; Y K Choi
Journal:  Korean J Intern Med       Date:  1987-07       Impact factor: 2.884
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.